[{"id":"22763cd5-04a0-4c19-8ce3-8bad45fab6c6","acronym":"CA209-8TX","url":"https://clinicaltrials.gov/study/NCT02960230","created_at":"2021-01-19T13:10:42.375Z","updated_at":"2025-02-25T14:36:49.894Z","phase":"Phase 1/2","brief_title":"H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas","source_id_and_acronym":"NCT02960230 - CA209-8TX","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02:01 • H3.3K27M • HLA-A*02 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • H3.3K27M • HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 11/18/2016","start_date":" 11/18/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-01-22"},{"id":"dbb9746a-5e33-42bd-bd36-aa05a815c4ff","acronym":"INTERCEPT-H3","url":"https://clinicaltrials.gov/study/NCT04808245","created_at":"2021-03-22T12:52:23.649Z","updated_at":"2024-07-02T16:35:11.107Z","phase":"Phase 1","brief_title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","source_id_and_acronym":"NCT04808245 - INTERCEPT-H3","lead_sponsor":"German Cancer Research Center","biomarkers":" IFNG","pipe":" | ","alterations":" H3.3K27M","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e H3.3K27M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zyclara (imiquimod)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-05"}]